Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143
Status:
Completed
Trial end date:
2017-02-24
Target enrollment:
Participant gender:
Summary
This single center first in human (FIH) study will comprise 2 parts; Part 1 will consist of 3
sequential dose groups (Groups A, B and C) and Part 2 will consist of 1 dose group (Group A).
There will be an option to include 2 additional dose groups in Part 1 (Groups D and E) to
assess alternative dose levels or formulations, if required.
In each study part, each subject will receive a single dose of investigational medicinal
product PWT-143 in each of 2 study periods (total of 2 single doses).